Slow release in every sense of the words.
Ultram is said to be one of the best medication on the online market. The simple rule is that the dose should be individualised so that each person takes the smallest dose required to produce the required relief from pain. Normally, this means that patients start with a very low daily dose and slowly increase the dosage every three days until a stable and effective concentration in the blood stream is achieved.
Usually this process is very and very slow. Reason of this is that FDA often uses strange tactiks of controlling advertisement. Applying the same caution may seem somewhat unfair given the significant increase in the cost of the process. As one firm say the FDA gave notice in May 2007 that a different statistical method was to be used to analyse the clinical data. This required further testing to produce more data compatible with the new method. The disagreement about methodology affected the extent to which the company could rely only on data produced from those completing the trials. The FDA was concerned that the exclusion of data from those dropping out of the trials could skew the results on safety. But, for all the delay, the company is confident that the once-daily version of ultram is effective and safe.
Let us assume that it is approved in the US and go back to the initial statement about dosage. At present, it is easy for people to forget when a dose is due. If you take too little dose, it will cause less problems than if you take too mush. Further, if a patient is on a four-hour schedule, this means waking during the night to maintain the required blood concentration. Labopharm Inc. believes that a once-daily regime will improve compliance. The evidence from the European markets on this point is encouraging.